hrcak mascot   Srce   HID

Izvorni znanstveni članak

Effects of Ramipril and Valsartan on Proteinuria and Renal Function in Patients with Nondiabetic Proteinuria

Marija Bilić
Radenka Munjas-Samarin
Danica Ljubanović
Ivica Horvatić
Krešimir Galešić

Puni tekst: engleski, pdf (106 KB) str. 1061-1066 preuzimanja: 310* citiraj
APA 6th Edition
Bilić, M., Munjas-Samarin, R., Ljubanović, D., Horvatić, I. i Galešić, K. (2011). Effects of Ramipril and Valsartan on Proteinuria and Renal Function in Patients with Nondiabetic Proteinuria. Collegium antropologicum, 35 (4), 1061-1066. Preuzeto s https://hrcak.srce.hr/75608
MLA 8th Edition
Bilić, Marija, et al. "Effects of Ramipril and Valsartan on Proteinuria and Renal Function in Patients with Nondiabetic Proteinuria." Collegium antropologicum, vol. 35, br. 4, 2011, str. 1061-1066. https://hrcak.srce.hr/75608. Citirano 24.08.2019.
Chicago 17th Edition
Bilić, Marija, Radenka Munjas-Samarin, Danica Ljubanović, Ivica Horvatić i Krešimir Galešić. "Effects of Ramipril and Valsartan on Proteinuria and Renal Function in Patients with Nondiabetic Proteinuria." Collegium antropologicum 35, br. 4 (2011): 1061-1066. https://hrcak.srce.hr/75608
Harvard
Bilić, M., et al. (2011). 'Effects of Ramipril and Valsartan on Proteinuria and Renal Function in Patients with Nondiabetic Proteinuria', Collegium antropologicum, 35(4), str. 1061-1066. Preuzeto s: https://hrcak.srce.hr/75608 (Datum pristupa: 24.08.2019.)
Vancouver
Bilić M, Munjas-Samarin R, Ljubanović D, Horvatić I, Galešić K. Effects of Ramipril and Valsartan on Proteinuria and Renal Function in Patients with Nondiabetic Proteinuria. Collegium antropologicum [Internet]. 2011 [pristupljeno 24.08.2019.];35(4):1061-1066. Dostupno na: https://hrcak.srce.hr/75608
IEEE
M. Bilić, R. Munjas-Samarin, D. Ljubanović, I. Horvatić i K. Galešić, "Effects of Ramipril and Valsartan on Proteinuria and Renal Function in Patients with Nondiabetic Proteinuria", Collegium antropologicum, vol.35, br. 4, str. 1061-1066, 2011. [Online]. Dostupno na: https://hrcak.srce.hr/75608. [Citirano: 24.08.2019.]

Sažetak
The renin-angiotensin system is involved in the progression of chronic renal disease of both diabetic and nondiabetic
origin. The angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers have been demonstrated to reduce
urinary protein excretion and attenuate the development of renal injury. This prospective, randomized, 12-month
study assessed the effects of ramipril (N=23) vs. valsartan (N=22) vs. combination of ramipril and valsartan (N=26) on
proteinuria, renal function and metabolic profile in 71 patients with nondiabetic proteinuria with normal or slightly impaired
renal function. Monotherapy with ramipril or valsartan and combination of these two drugs significantly reduced
proteinuria, serum creatinine, cholesterol and triglycerides as well as systolic and diastolic arterial blood pressure.
There was no significant difference among three study groups according to reduction of arterial blood pressure,
serum cholesterol and triglycerides. At one year, a significant reduction in serum creatinine was recorded in all three
study groups, whereas at 3 and 6 months a statistically significant reduction in serum creatinine was only observed in
patients on combination therapy. In addition, at 3 months the reduction of proteinuria was significantly greater in patients
on combination therapy than in those on either monotherapy. These results indicated the combination therapy with
angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers to be more efficacious than either monotherapy
in reducing proteinuria and serum creatinine level in the first 3 (proteinuria and serum creatinine) or 6 (serum
creatinine) months of treatment.

Ključne riječi
angiotensin-converting enzyme inhibitors; angiotensin II receptors blockers; proteinuria; renoprotection

Hrčak ID: 75608

URI
https://hrcak.srce.hr/75608

Posjeta: 456 *